Medicare Coverage for GLP-1 Weight Loss Drugs: What You Need to Know

For years, Medicare beneficiaries heard the same frustrating answer: weight loss medications aren't covered. That changed in July 2026 when Medicare launched the glucagon-like peptide-1 (GLP-1) Bridge Program, giving eligible beneficiaries access to medications like Wegovy® and Zepbound® with costs as low as $50/month for eligible beneficiaries, subject to program terms and eligibility; costs may vary.

The shift is significant, but it comes with specific eligibility requirements, covered medications, and limitations worth knowing before you assume you qualify for Wegovy® or Zepbound®. Here's how the program works, who's eligible, and what to do if you don't meet the criteria.

Does Medicare cover GLP-1 medications for weight loss?

For a long time, the answer was no. Standard Medicare Part D plans have excluded medications prescribed solely for weight loss, even FDA-approved GLP-1 medications like Wegovy® and Zepbound®. But that changed in July 2026 when Medicare launched the GLP-1 Bridge Program, a temporary pilot that gives eligible beneficiaries access to certain weight loss medications with costs as low as $50/month for eligible beneficiaries, subject to program terms and eligibility; costs may vary.

If you've asked about Medicare weight loss medication coverage before and been told it wasn't an option, it's worth checking again. The Bridge Program runs through December 2027 and covers specific GLP-1 medications, though not all of them and not every formulation.

Standard Part D plans may still cover GLP-1s when prescribed for other FDA-approved uses, like type 2 diabetes, obstructive sleep apnea, or cardiovascular risk reduction in people with overweight or obesity. The Bridge Program, however, specifically addresses coverage for weight loss.

What is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge Program is a temporary demonstration project that expands access to anti-obesity medications for Medicare beneficiaries. It operates outside of standard Part D coverage, meaning you don't receive medications through your regular prescription drug plan.

Instead, eligible beneficiaries access covered GLP-1 medications directly through the Bridge Program with costs as low as $50/month for eligible beneficiaries. The program was created to address a gap in Medicare coverage and recognizes that obesity is a chronic disease that often requires medical treatment beyond diet and exercise alone.

Think of it as a bridge between current coverage limitations and potential future policy changes. The program gives Medicare beneficiaries temporary access to medications that can support meaningful weight loss while policymakers evaluate longer-term solutions.

Who qualifies for Medicare GLP-1 coverage?

Not everyone with Medicare automatically qualifies. The Bridge Program has specific eligibility requirements:

• Medicare Part D enrollment: You have to be enrolled in a Medicare Part D plan, either as a stand-alone plan or through a Medicare Advantage plan that includes drug coverage.
• No existing coverage: Your current Medicare drug plan can't already cover the GLP-1 medication you're seeking for weight loss.
• Clinical criteria:To qualify, you'll need to meet BMI and health requirements determined during a clinical evaluation. In general, eligibility includes:
  • BMI of 35 or higher, or
  • BMI of 30–34.9 with at least one qualifying health condition (such as heart failure, uncontrolled high blood pressure affecting 62% of beneficiaries, chronic kidney disease, or prediabetes), or
  • BMI of 27–29.9 with prediabetes or a history of heart attack, stroke, or symptomatic peripheral artery disease.

Eligibility depends on medical criteria, not simply wanting to lose weight. A clinician reviews your health history, current medications, and weight-related health conditions to determine whether GLP-1 treatment is appropriate for you.

Tip: Found offers a free GLP-1 Coverage Checker that contacts your insurer directly and provides a personalized report showing your coverage details, estimated costs, and whether prior authorization is required. You don't have to sign up for treatment to use it.

Which GLP-1 medications are covered?

The Bridge Program covers certain medications and formulations; covered options may change. Not every GLP-1 on the market qualifies, and even within covered medications, only certain forms are included.

The distinction between formulations matters. If your clinician prescribes Zepbound® vials, for example, the Bridge Program won't cover them. Only the KwikPen formulation qualifies.

Wegovy® now comes in both injectable and oral tablet forms. The tablet contains the same active ingredient as the injection (semaglutide) and is the first FDA-approved oral GLP-1 medication for weight loss. Both formulations are covered through the Bridge Program.

How much do GLP-1 medications cost through Medicare?

Through the Medicare GLP-1 Bridge Program, costs are as low as $50/month for eligible beneficiaries, subject to program terms and eligibility; costs may vary. Without insurance coverage, GLP-1 medications can cost $936 to $1,349 per month, so the Bridge Program represents a significant reduction in out-of-pocket costs.

However, the pricing only applies to medications obtained through the Bridge Program, not through your standard Part D plan.

If you receive a GLP-1 through standard Part D coverage for a non-weight-loss indication like type 2 diabetes, your cost depends on your specific plan's formulary, tier placement, and deductible structure.

A few things to keep in mind:

• Membership costs are separate: If you work with a weight care platform like Found, your membership fee covers clinician visits, insurance navigation, ongoing support, and care coordination. Medication costs are separate.
• Pricing can change: The Bridge Program is temporary, and terms may evolve.
• Eligibility isn't guaranteed: Final determination depends on meeting program requirements.

How to get GLP-1 medication through Medicare

Getting started involves several steps, though working with a weight care provider can simplify the process.

1. Confirm your Medicare Part D enrollment

You'll have active Part D coverage, either through a stand-alone prescription drug plan or a Medicare Advantage plan with drug benefits.

2. Check your eligibility

Checking eligibility involves verifying that your current plan doesn't already cover the medication for weight loss and that you meet the clinical criteria. Found's free coverage checker can help determine your eligibility before you commit to treatment.

3. Complete a clinical evaluation

A licensed clinician reviews your health history, current medications, BMI, and any weight-related health conditions. GLP-1 medications aren't appropriate for everyone, and the evaluation determines whether they're right for you.

4. Navigate prior authorization

Many insurance plans, including Medicare, require prior authorization before covering GLP-1 medications. Prior authorization means your clinician submits documentation showing medical necessity. Found handles the prior authorization process for members, reducing the administrative burden.

5. Receive your medication

Once approved, covered medications can be delivered to your door. Ongoing care includes regular check-ins with your clinician to monitor progress, adjust dosing, and address any side effects.

Limitations of the Medicare GLP-1 Bridge Program

While the Bridge Program represents meaningful progress, it has important limitations.

The program is temporary. It runs through December 2027. What happens after that remains uncertain, though expanding coverage would cost $35 billion through 2034 according to Congressional Budget Office projections.

Not all medications qualify. The Bridge Program covers certain medications and formulations; covered options may change. Other GLP-1 medications like Ozempic® (approved for diabetes, not weight loss) and Mounjaro® aren't included in the Bridge Program for weight loss purposes.

Formulation matters. Even within covered medications, only specific formulations qualify. Zepbound® vials, for instance, aren't covered. Only the KwikPen is.

Government insurance exclusions apply elsewhere. While the Bridge Program creates an exception, other manufacturer savings programs like NovoCare typically exclude Medicare beneficiaries. The Bridge Program pricing is specific to the demonstration project.

Clinical criteria apply. Coverage depends on meeting medical eligibility requirements, not simply requesting the medication.

What if you don't qualify for the Bridge Program?

If you don't meet the eligibility requirements for the Medicare GLP-1 Bridge Program, you still have options.

Standard Part D coverage for other indications: If you have type 2 diabetes, obstructive sleep apnea, or meet criteria for cardiovascular risk reduction, your Part D plan may cover GLP-1 medications for those purposes. Weight loss can be a beneficial effect of treatment for those conditions.

Cash-pay options: Some manufacturer programs offer discounted pricing for self-pay patients. Wegovy® injectable has introductory pricing through NovoCare, and Zepbound® offers discounted vial pricing through LillyDirect. However, manufacturer savings programs typically exclude Medicare beneficiaries, so eligibility varies.

Alternative medications: GLP-1s aren't the only option for medically supported weight loss. Other FDA-approved medications may be appropriate depending on your health profile. A weight care specialist can help identify alternatives that might work for your situation.

Comprehensive weight care: Medication is one tool among many. Sustainable weight loss often involves addressing the biological, behavioral, and lifestyle factors that contribute to weight challenges. Working with a clinician who specializes in weight care can help you develop a personalized approach, with or without GLP-1 medication.

Found is among the largest medically-supported telehealth weight care platforms in the country, having served more than 250,000 members to date. To discover your MetabolicPrint™ and start your journey with Found, take our quiz. *Individual results may vary.

Frequently asked questions

Is the Medicare GLP-1 Bridge Program permanent?

No. The Bridge Program is a temporary demonstration project running from July 1, 2026, through December 2027. Future coverage depends on policy decisions that haven't been finalized yet.

Can I use manufacturer savings cards with Medicare?

Generally, no. Most manufacturer savings programs, like NovoCare for Wegovy® or LillyDirect for Zepbound®, exclude patients with government insurance, including Medicare and Medicaid. The Bridge Program's pricing is a separate arrangement specific to the demonstration project.

What's the difference between Wegovy® and Ozempic®?

Both contain the same active ingredient (semaglutide), but they're FDA-approved for different purposes. Wegovy® is approved for chronic weight management, while Ozempic® is approved for type 2 diabetes. The Bridge Program covers Wegovy® for weight loss but doesn't cover Ozempic® for that purpose.

Do I have to use a specific pharmacy?

The Bridge Program may have pharmacy requirements that differ from your standard Part D plan. Your clinician or weight care provider can help you understand where to fill your prescription to receive the program pricing.

What happens if I start the Bridge Program and it ends before I reach my goals?

Working with a comprehensive weight care provider means you'll have ongoing support to navigate coverage changes, explore alternatives, and maintain your progress regardless of policy shifts.

Found is not affiliated with or endorsed by Eli Lilly and Company, the manufacturer of Zepbound®, Mounjaro®, and other GLP-1 medications. Found is not affiliated with or endorsed by Novo Nordisk, the manufacturer of Wegovy®, Ozempic®, Saxenda®, and other GLP-1 medications. Prescriptions are provided only if clinically appropriate after evaluation by a licensed provider.